Abstract:Background: Air tamponade’s effectiveness in treatment of rhegmatogenous retinal detachment (RRD) remains unclear.
Objective: We aimed to review the surgical outcomes between air and gas tamponade after vitrectomy for RRD.
Method: PubMed, Cochrane Library, EMBASE, and Web of Science were reviewed. The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO CRD42022342284). The primary outcome was the primary anatomical success after vitrectomy. The secondary outc… Show more
“…Ten studies with 2,677 eyes were included, of which 1,556 eyes received different types of gas tamponades and the remainder an air tamponade. The reported primary anatomical success rates with gas tamponades range from 78.1 to 100% with different gas tamponades, [ 11 ] similar to our study. The lowest rate was in a prospective study with C3F8 gas tamponade in inferior breaks, with a success rate of 78.13% in 32 eyes [ 18 ].…”
Section: Discussionsupporting
confidence: 89%
“…In the current literature, air tamponades have been compared with different gas tamponades in rhegmatogenous retinal detachment with regard to re-detachment rate, with some studies reporting higher surgical success rates with gas tamponades and others finding no difference [ 1 , 10 , 11 ]. However, available comparative data on long- and short-acting gas tamponades in standard retinal detachment surgery is sparse.…”
Background
In vitrectomy for rhegmatogenous retinal detachment, long-acting gas tamponades (LGT) such as C3F8 or C2F6 may improve surgical success rate due to their prolonged effect compared to a short-acting gas tamponade (SGT) with SF6. On the other hand, SGT allow a significantly faster visual rehabilitation after surgery and may reduce the risk of gas-related complications. As comparative data in retinal detachment surgery is limited, we assessed the outcomes of vitrectomies using either LGT or SGT.
Methods
We retrospectively analyzed 533 eyes of 524 consecutive patients diagnosed with primary rhegmatogenous retinal detachment not complicated by proliferative vitreoretinopathy (PVR) and treated by vitrectomy at two clinical sites. Depending on the site the patients presented at, they received either preferentially LGT (study site 1) or SGT (study site 2). Retinal re-detachment rates during a period of 6 months following surgery were analyzed.
Results
At study site 1, 254 of 278 eyes (91.4%) were treated by LGT (C3F8 72.3%; C2F6 19.1%), whereas at study site 2, 246 of 255 eyes (96.5%) received SGT (SF6). Rates of retinal re-detachment in the LGT- and SGT-treated groups were similar with 23 of 254 eyes (9.1%) and 24 of 246 eyes (9.8%), respectively (p = 0.9). Median time to re-detachment was 5.7 weeks in the LGT-treated group and 4.4 weeks in the SGT-treated group (p = 0.4).
Conclusion
In rhegmatogenous retinal detachment repair by vitrectomy, the use of SGT results in comparable rates of successful retinal re-attachment as LGT. Given the faster visual rehabilitation with SGT, these results suggest SGT as a sensible alternative to LGT in surgery of retinal detachment without PVR.
“…Ten studies with 2,677 eyes were included, of which 1,556 eyes received different types of gas tamponades and the remainder an air tamponade. The reported primary anatomical success rates with gas tamponades range from 78.1 to 100% with different gas tamponades, [ 11 ] similar to our study. The lowest rate was in a prospective study with C3F8 gas tamponade in inferior breaks, with a success rate of 78.13% in 32 eyes [ 18 ].…”
Section: Discussionsupporting
confidence: 89%
“…In the current literature, air tamponades have been compared with different gas tamponades in rhegmatogenous retinal detachment with regard to re-detachment rate, with some studies reporting higher surgical success rates with gas tamponades and others finding no difference [ 1 , 10 , 11 ]. However, available comparative data on long- and short-acting gas tamponades in standard retinal detachment surgery is sparse.…”
Background
In vitrectomy for rhegmatogenous retinal detachment, long-acting gas tamponades (LGT) such as C3F8 or C2F6 may improve surgical success rate due to their prolonged effect compared to a short-acting gas tamponade (SGT) with SF6. On the other hand, SGT allow a significantly faster visual rehabilitation after surgery and may reduce the risk of gas-related complications. As comparative data in retinal detachment surgery is limited, we assessed the outcomes of vitrectomies using either LGT or SGT.
Methods
We retrospectively analyzed 533 eyes of 524 consecutive patients diagnosed with primary rhegmatogenous retinal detachment not complicated by proliferative vitreoretinopathy (PVR) and treated by vitrectomy at two clinical sites. Depending on the site the patients presented at, they received either preferentially LGT (study site 1) or SGT (study site 2). Retinal re-detachment rates during a period of 6 months following surgery were analyzed.
Results
At study site 1, 254 of 278 eyes (91.4%) were treated by LGT (C3F8 72.3%; C2F6 19.1%), whereas at study site 2, 246 of 255 eyes (96.5%) received SGT (SF6). Rates of retinal re-detachment in the LGT- and SGT-treated groups were similar with 23 of 254 eyes (9.1%) and 24 of 246 eyes (9.8%), respectively (p = 0.9). Median time to re-detachment was 5.7 weeks in the LGT-treated group and 4.4 weeks in the SGT-treated group (p = 0.4).
Conclusion
In rhegmatogenous retinal detachment repair by vitrectomy, the use of SGT results in comparable rates of successful retinal re-attachment as LGT. Given the faster visual rehabilitation with SGT, these results suggest SGT as a sensible alternative to LGT in surgery of retinal detachment without PVR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.